Magnesium Bisglycinate Shows Modest Sleep Benefits in Randomized Trial

Sleep disturbances affect one-third of the global population, with 6-15% meeting clinical criteria for insomnia disorders. While cognitive behavioral therapy remains the gold standard treatment, growing interest exists in nutritional interventions like magnesium supplementation, which plays essential roles in sleep regulation through mechanisms involving melatonin production and cortisol reduction.

This four-week, double-blind, placebo-controlled trial enrolled 155 healthy German adults aged 18-65 with self-reported poor sleep quality (Regensburg Insomnia Scale score >12). Participants were randomly assigned to receive either 250mg elemental magnesium as bisglycinate (also providing 1.5g glycine) or identical placebo capsules taken 30-60 minutes before bedtime. The primary outcome was insomnia severity measured by the Insomnia Severity Index (ISI), with additional assessments of sleep quality, fatigue, mood, and stress.

The magnesium group demonstrated significantly greater improvement in ISI scores from baseline to week 4 compared to placebo (-3.9 vs -2.3 points, p=0.049). However, the effect size was small (Cohen's d=0.2), indicating modest clinical benefit. No significant differences emerged in secondary outcomes including sleep quality scales, fatigue measures, or psychological assessments. Notably, exploratory analysis revealed potentially greater improvements among participants reporting lower baseline dietary magnesium intake, suggesting a subgroup of high responders.

These findings provide evidence supporting magnesium bisglycinate's modest benefits for insomnia symptoms in healthy adults with poor sleep. The chelated form may offer advantages through enhanced bioavailability and potential synergistic effects with glycine. However, the small effect size and lack of objective sleep measurements limit clinical interpretation.

Future research should incorporate objective sleep assessments like polysomnography or actigraphy, extend intervention periods beyond four weeks, and systematically characterize potential high responders through comprehensive dietary magnesium assessment and biomarker analysis. The study's real-world, home-based design enhances external validity while highlighting magnesium supplementation as a safe, accessible option for individuals seeking natural sleep support.